Abstract
The first clinical trial for gene transfer in humans was approved in the United States in 1989. In this trial, genetically marked lymphocytes that had been removed from a melanoma biopsy were transduced with a retroviral vector containing the gene conferring resistance to the neomycin analogue G-418, propagated ex vivo and returned to the patient. The purpose of this gene marking study was to determine if the G-418 resistant lymphocytes honed specifically to melanoma and to determine the lifespan of the marked lymphocytes. Results of various gene marker trials have been published (Dunbar et al. 1994; Brenner 1996). Marker trials have demonstrated some homing to tumors, and marked lymphocytes have been detectable for years past re-infusion.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Anderson WF (1993) What about these monkeys that got T-cell lymphoma? Hum Gen Ther 4:1–2
Anderson WF, McGarrity GJ, Moen RC (1993) Report to the NIH Recombinant DNA Advisory Committee on murine replication competent retroviruses (RCR) assays. Hum Gen Ther 4:311–321
Blaese RM, Culver KW, Miller AD et al. (1995) T-lymphocyte directed gene therapy for ADA-SCID: initial trial results after 4years. Science 270:475–480
Brenner MK (1996) Gene marking. Hum Gen Ther 7:1927–1936
Cornetta K, Morgan RA, Anderson WF (1991) Safety issues related to retroviralmediated gene transfer. Hum Gen Ther 2:5–14
Donahue RE, Kessler SW, Bodine D et. al. (1992) Helper virus induced T-cell lymphoma in non-human primates after retroviral mediated gene transfer. J Exp Med 176:1125–1135
Dunbar CE, Emmons RVB (1994) Gene transfer into hematopoeitic progenitor and stem cells; progress and problems. Stem Cells 12:563–576
Feigner PL (1996) Improvements in cationic liposomes for in vivo gene transfer. Hum Gen Ther 7:1791–1793
Fisher KJ, Gao GP, Weitzman MD, DeMattio R, Burda JF, Wilson JM (1996) Transduction with recombinant adeno-associated virus for gene therapy is limited by leading strand synthesis. J Virol 70:520–532
Kohn DB, Weinberg KI, Nolta JA, et. al. (1995) Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Nat Med 1:1017–1023
McGarrity GJ, Chiang YL (1997) Gene therapy of local tumors. In: Lotze M, Rubin R (ed) Regional therapy of advanced cancer. Lippincott-Raven, pp 375–390
Miller AD (1990) Retroviral packaging cells. Hum Gen Ther 1:5–14
Miller AD, Buttimore C (1986) Redesign of retropackaging cell lines to avoid recombination leading to helper virus production. Mol Cell Biol 6:2895–2902
Shenk T (1995) Group C adenoviruses as vectors for gene therapy. Viral Vectors 89–107
Stephan DJ, Yang Z-Y, Shan H, Simari RD, Wheeler CJ, Feigner PL, Gordon D, Nabel GJ, Nabel EG (1996) A new cationic liposome DNA complex enhances the efficiency of arterial gene transfer in vivo. Hum Gen Ther 7:1803–1812
Wolff JA, Malone RW, Williams P, Chong W, Ascadi G, Jariu P, Feigner PL (1990) Direct gene transfer into mouse muscle in vivo. Science 247:1465–1468
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
McGarrity, G.J. (1998). Human Gene Therapy: Review and Outlook. In: Clynes, M. (eds) Animal Cell Culture Techniques. Springer Lab Manual. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-80412-0_33
Download citation
DOI: https://doi.org/10.1007/978-3-642-80412-0_33
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-63008-1
Online ISBN: 978-3-642-80412-0
eBook Packages: Springer Book Archive